The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study

• Published in: Antioxidants Vol. 11; no. 10; p. 1878
• Main Authors: Pignatelli, Pasquale, Baratta, Francesco, Buzzetti, Raffaella, D'Amico, Alessandra, Castellani, Valentina, Bartimoccia, Simona, Siena, Antonio, D'Onofrio, Luca, Maddaloni, Ernesto, Pingitore, Annachiara, Chiariello, Giovanni Alfonso, Santilli, Francesca, Pastori, Daniele, Cocomello, Nicholas, Violi, Francesco, Del Ben, Maria, Cammisotto, Vittoria, Carnevale, Roberto
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.09.2022; MDPI
• Subjects: Blood clots; Blood platelets; Collagen; CYBB protein; Diabetes; Diabetes mellitus (non-insulin dependent); Down-regulation; gliflozins; Glucose; Glucose metabolism; Glucose transporter; Heart failure; Hydrogen peroxide; Immunoassay; Ligands; Metformin; Mortality; Observations; Oxidants; Oxidative stress; Patients; platelet activation; Platelets; Thrombosis; type 2 diabetes; Values; United States; St Louis Missouri; United States > US; thrombosis; type 2 diabetes; gliflozins; oxidative stress; platelet activation

Sodium−glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2 diabetes (T2D). As platelet activation and oxidative stress play a key role in atherothrombotic-related complications, we hypothesized that gliflozi...